Patients included in the clinical study were after autologous and T cell-depleted allogeneic bone marrow transplantation and did not have ongoing GVHD at the start of IL-2 therapy, thus it is thought that the patients were in the immune-tolerant state. Here, IL2 is linked to graft versus host disease.